RECRUITING

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

Talk to us

Conditions

CADASILneurodegenerationdementiacognitive impairmentNOTCH3vascular dementia

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.

Official Title

Unraveling the Early Phases of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)

Quick Facts

Study Start:2022-06-03
Study Completion:2026-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05677880

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. History of severe learning disability, intellectual disability, or other neurological disease or event not attributable to CADASIL
  2. 2. History of serious alcohol or drug abuse within the past year
  3. 3. Unwilling to undergo NOTCH3 genetic testing if there is no test on file

Contacts and Locations

Study Contact

Cadasil Consortium
CONTACT
1-833-795-3016
info@cadasil-consortium.org

Principal Investigator

Jane S Paulsen, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Michael D Geschwind, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California
Los Angeles, California, 90095
United States
University of California
San Francisco, California, 94143
United States
University of Colorado
Denver, Colorado, 80204
United States
Georgia State University Research Foundation
Atlanta, Georgia, 30303
United States
Loyola University
Chicago, Illinois, 60660
United States
Columbia University
New York City, New York, 10027
United States
Oregon Health & Science University
Portland, Oregon, 97239
United States
Brown University
Providence, Rhode Island, 02912
United States
University of Texas Health Science Center
Houston, Texas, 77030
United States
University of Texas
San Antonio, Texas, 78249
United States
University of Utah
Salt Lake City, Utah, 84112
United States
University of Washington
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Jane S Paulsen, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison
  • Michael D Geschwind, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-03
Study Completion Date2026-01

Study Record Updates

Study Start Date2022-06-03
Study Completion Date2026-01

Terms related to this study

Keywords Provided by Researchers

  • neurodegeneration
  • dementia
  • cognitive impairment
  • NOTCH3
  • vascular dementia

Additional Relevant MeSH Terms

  • CADASIL